Experienced healthcare exec with a multi-disciplinary background in corporate strategy, business development, corporate venture capital and financial management with large and emerging healthcare companies. Previously, Head of Corporate Strategy & Sr. Director, New Ventures at Lundbeck, Director, Corporate Development at Ovation Pharmaceuticals, Inc., - sold to Lundbeck for $900M. Finance and clinical development with Pfizer and Eli Lilly. BS in

Head of the Department of Urology & Professor in the Dept. of Bioengineering at the University of Illinois at Chicago. Editorship positions with the Journal of Urology, including Co-Editor In Chief of Fertility and Sterility, Practical Reviews in Urology, the Journal of Andrology and Urology Times. Earned MD from the University of Pittsburgh, Surgery and Urology residencies at Michael Reese Hospital and UIC, fellowship in Andrology at the Baylor

Professor and Director of Pelvic Health and Reconstructive Urology in at the University of Illinois at Chicago. Specializes in minimally invasive procedures for stress urinary incontinence, pelvic floor reconstruction and less invasive urodynamics assessments. Board of International Continence Society. Associate Editor of the International Urogynecology Journal. MD from the University of Trieste, Urology residency at the University Milan, Italy.